In view of the fact that during previous small‐scale clinical studies conducted in MTC patients other CCK2R‐targeting peptide analogues elicited transient adverse effects, the toxicity of the CP04 precursor was extensively tested in two animal species. Here, CCKBR is linked to medullary thyroid gland carcinoma.